logo
  •  

    (860) 422-4747

    Info@pprxsolutions.com

  • Home
  • About Us
  • Pharmacogenetics
  • Our Blog
  • Programs
  • Contact Us
  • Home
  • About Us
  • Pharmacogenetics
  • Our Blog
  • Programs
  • Contact Us

Behind the Push to Keep Higher-Priced EpiPen in Consumers’ Hands- TheWallStreetJournal.com

Home » Uncategorized » Behind the Push to Keep Higher-Priced EpiPen in Consumers’ Hands- TheWallStreetJournal.com
crop-di
August 9, 2017

Behind the Push to Keep Higher-Priced EpiPen in Consumers’ Hands- TheWallStreetJournal.com

By George McDonald Uncategorized No comment

This is a strange twist probably driven by lucrative rebates. Read more from The Wall Street Journal:

https://www.wsj.com/articles/behind-the-push-to-keep-higher-priced-epipen-in-consumers-hands-1502036741

 

 

  • Facebook
  • LinkedIn
  • When are Cheap OTC Drugs Specialty Drugs? – Healthblog.ncpa.org
  • Pharmacy Benefit Managers Are Still Squeezing Drugmakers For Discounts- Bloomberg.com

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Recent Posts

  • Doctor and Hospital Groups Fighting a Measure to Rein In State Drug Costs – StatNews.com
  • Do Pharma’s Claims On Drug Prices Pass The Smell Test? – KHN.org
  • Genetics Testing and the Opioid Epidemic
  • The FDA Just Approved the First Direct Competitor to a Billion-Dollar Cancer Drug – BusinessInsider.com
  • Americans Would Save $7B Buying Prescription Drugs From Canada – UPI.com

Categories

  • Insurance
  • Uncategorized
Copyright @ 2019 PPRx Solutions
  • Legal
  • Privacy Statement